MAP2K7 and neoplasm: Targets BRAF, a protein kinase that is part of the MAPK pathway that is dysregulated and overactive in cancers. BRAF mediates signaling from RAS to MEK in the Ras/Raf/MEK/ERK pathway. Inhibiting BRAF kinase interferes with the MAPK pathway of cancer cells and leads to a reduction in tumor growth.